The Patent Finder
KP

Kalvista Pharmaceuticals Limited

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

4 patents currently held

8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2032. from the record

Of the 8 now held by other companies, 8 name Dri UK LP as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2032
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 9, 2026
    The maintenance fee for Benzylamine Derivatives as Inhibitors of Plasma Kallikrein (US 9,051,249) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,051,249Benzylamine Derivatives as Inhibitors of Plasma Kallikrein
In force
 · High confidence
In forceHigh confidence
US 10,221,161Inhibitors of Plasma Kallikrein
In force
 · High confidence
In forceHigh confidence
US 11,584,735Solid Forms of a Plasma Kallikrein Inhibitor and Salts Thereof
In force
 · High confidence
In forceHigh confidence
US 11,613,527Enzyme Inhibitors
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 8 patents in force now held by others · 13 patents ended · 9 applications pending · 18 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited